FDA Commissioner Calls For Sarepta Drug Study To Be Retracted

Sep 22, 2016, 12:01 by Michael Croft

STAT | The study explored whether the Sarepta drug for Duchenne muscular dystrophy can sufficiently produce higher levels of a protein that provides mobility.

September 22, 2016 | The study explored whether the Sarepta drug for Duchenne muscular dystrophy can sufficiently produce higher levels of a protein that provides mobility. STAT